Skip to main content
Clinical Trials/NCT04221854
NCT04221854
Unknown
Not Applicable

Stool-based SDC2 DNA Methylation Test vs. Fecal Immunochemical Test on the Detection of Colorectal Advanced Adenomatous Polyps and Cancer in Chinese Population: A Multi-central Randomized Clinical Trial

Sixth Affiliated Hospital, Sun Yat-sen University8 sites in 1 country50,000 target enrollmentJanuary 6, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Enrollment
50000
Locations
8
Primary Endpoint
The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods
Last Updated
6 years ago

Overview

Brief Summary

The primary objective is to compare the performance of Stool-based SDC2 DNA Methylation Test and commercially available Fecal Immunochemical Test(FIT) , on the detection rate of advanced adenomatous polyps and colorectal cancer in Chinese population. Subjects with positive results in either test will receive colonoscopy. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

Detailed Description

A large cohort of participants will be asked to collect stool sample for either Stool-based SDC2 DNA Methylation Test or Fecal Immunochemical Test. Subjects who have positive results will undergo colonoscopy within 6 months. Representative histopathology slides from tissue biopsied or excised during colonoscopy and those from subsequent definitive surgery may be retrieved in order to be evaluated by pathologists to confirm the diagnosis and staging.

Registry
clinicaltrials.gov
Start Date
January 6, 2020
End Date
December 31, 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Responsible Party
Principal Investigator
Principal Investigator

Ping Lan

Professor

Sixth Affiliated Hospital, Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

  • Subject is average risk for development of colorectal cancer.
  • Subject is able and willing to undergo a screening colonoscopy within six months of enrollment.
  • Subject is 45 to 80 years of age inclusive.
  • Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
  • Subject is able and willing to provide stool samples according to written instructions provided to them.

Exclusion Criteria

  • Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
  • Subject has a history of colorectal cancer or adenoma.
  • Subject has a history of other digestive tract cancer.

Outcomes

Primary Outcomes

The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods

Time Frame: One year

The stool-based SDC2 DNA methylation test CT values of 38 or less compared to beta-actin considered to be positive. Fecal immunochemical test values of more than 100 ng of hemoglobin per milliliter of buffer were considered as positive. An optical colonoscopy is used as diagnostic method. Lesions will be confirmed by histopathologic examination.

Study Sites (8)

Loading locations...

Similar Trials